TNF and neoplasm: CAR-T cell targeting of FRβ+ TAMs will result in FRβ− (M1 phenotype) TAMs becoming predominant in the tumour stroma, creating an anti-tumour environment by the release of proinflammatory cytokines such as TNFα.